ALERT: This system is being upgraded on Tuesday December 12. It will not be available
for use for several hours that day while the upgrade is in progress. Deposits to DukeSpace
will be disabled on Monday December 11, so no new items are to be added to the repository
while the upgrade is in progress. Everything should be back to normal by the end of
day, December 12.
Acute Limb Ischemia in Peripheral Artery Disease.
Abstract
BACKGROUND:Acute limb ischemia (ALI) is an important clinical event and an emerging
cardiovascular clinical trial outcome. Risk factors for and outcomes after ALI have
not been fully evaluated. METHODS:EUCLID (Examining Use of Ticagrelor in Peripheral
Artery Disease) randomized patients with peripheral artery disease to ticagrelor versus
clopidogrel. Enrollment criteria included an ankle-brachial index ≤0.80 or previous
lower extremity revascularization. Patients were grouped according to the primary
outcome, postrandomization ALI hospitalization. Baseline factors associated with ALI
were identified using Cox proportional hazards modeling. Models with ALI hospitalization
as a time-dependent covariate were developed for secondary outcomes of major adverse
cardiovascular events (myocardial infarction, cardiovascular death, ischemic stroke),
all-cause mortality, and major amputation. RESULTS:Among 13 885 patients, 1.7% (n=232)
had 293 ALI hospitalizations (0.8 per 100 patient-years). Patients with versus without
ALI were younger and more often had previous peripheral revascularization and lower
baseline ankle-brachial index. Treatment during ALI hospitalization included endovascular
revascularization (39.2%, n=115), surgical bypass (24.6%, n=72), and major amputation
(13.0%, n=38). After multivariable adjustment, any previous peripheral revascularization
(Hazard Ratio [HR] 4.7, 95% CI 3.3-6.8, P<0.01), baseline atrial fibrillation (HR
1.8, 95% CI 1.1-3.2, P=0.03), and baseline ankle-brachial index ≤0.60 (HR 1.3 per
0.10 decrease, 95% CI 1.1-1.5, P<0.01) were associated with higher ALI risk. Older
age (HR 0.8 per 10-year increase, 95% CI 0.7-1.0, P=0.02) and baseline statin use
(HR 0.7, 95% CI 0.5-0.9, P<0.01) were associated with lower risk for ALI. There was
no relationship between randomized treatment to ticagrelor or clopidogrel and ALI.
Among patients with previous revascularization, surgical versus endovascular procedures
performed more than 6 months prior were associated with ALI (adjusted HR 2.63, 95%
CI 1.75-3.96). In the overall population, ALI hospitalization was associated with
subsequent MACE (adjusted HR 1.4, 95% CI 1.0-2.1, P=0.04), all-cause mortality (adjusted
HR 3.3, 95% CI 2.4-4.6, P<0.01), and major amputation (adjusted HR 34.2, 95% CI 9.7-20.8,
P<0.01). CONCLUSIONS:Previous peripheral revascularization, baseline atrial fibrillation,
and lower ankle-brachial index identify peripheral artery disease patients at heightened
risk for ALI, an event associated with subsequent cardiovascular and limb-related
morbidity and mortality. CLINICAL TRIAL REGISTRATION:URL: https://www.clinicaltrials.gov.
Unique identifier: NCT01732822.
Type
Journal articlePermalink
https://hdl.handle.net/10161/19416Published Version (Please cite this version)
10.1161/circulationaha.119.039773Publication Info
Hess, Connie N; Huang, Zhen; Patel, Manesh R; Baumgartner, Iris; Berger, Jeffrey S;
Blomster, Juuso I; ... Hiatt, William R (2019). Acute Limb Ischemia in Peripheral Artery Disease. Circulation, 140(7). pp. 556-565. 10.1161/circulationaha.119.039773. Retrieved from https://hdl.handle.net/10161/19416.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
William Schuyler Jones
Associate Professor of Medicine
I am an interventional cardiologist with a specific focus on the diagnosis and treatment
of patients with cardiovascular disease. As a clinician, I see patients in the office
and do coronary and peripheral vascular procedures (angiography and interventions)
in the Duke Cardiac Catheterization Laboratory. I have served as the Medical Director
of the cath lab at Duke since 2016. Alongside my partners in the cath lab, we collaborate
with our cardiothoracic surgeons to hold Heart Team meetings each
Manesh Raman Patel
Richard Sean Stack, M.D. Distinguished Professor
Manesh Patel is the Chief of the Division of Cardiology and the Division of Clinical
Pharmacology. His clinical interests include diagnostic and interventional coronary
angiography, peripheral angiography and endovascular intervention. His is involved
in several clinical trials involving patients with cardiovascular disease and in cardiac
imaging. He is also the Chair of the American College of Cardiology Task Force for
Appropriate Use Criteria for Cardiovascular Procedures and
Frank Wesley Rockhold
Professor of Biostatistics & Bioinformatics
Frank is a full time Professor of Biostatistics and Bioinformatics and Faculty Director
for Biostatistics at Duke University Medical Center, Affiliate Professor of Biostatistics
at Virginia Commonwealth University, and Strategic Consultant at Hunter Rockhold,
Inc. His 40+-year career includes senior research positions at Lilly, Merck, and
GlaxoSmithKline, where he retired as Chief Safety Officer and Senior Vice President
of Global Clinical Safety and Pharmacovigilance. He h
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info